Iovance raises FY2026 revenue guidance to $410-$420M from $350-$370M on Amtagvi, Proleukin demand

IOVANCE BIOTHERAPEUTICS, INC.

FY2026 total revenue guidance raised to $410-$420M, up $55M (~15%) at the midpoint from the prior $350-$370M range; implies nearly 60% annual growth.
Iovance most recently reported record Q2 2026 total product revenue of $99.3M, driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin.
Authorized treatment center (ATC) network has grown to ~100 centers, with expansion to at least 110 ATCs expected by year-end 2026.
Interim CEO Frederick Vogt cites current manufacturing schedule as giving strong visibility into Q3 and Q4 revenues, plus efficiencies accelerating progress toward profitability.
Q3 2026 financial results expected in early November 2026; this update completes the guidance review announced with Q2 results.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.